[1] |
Könnecke H, Bechmann I. The role of microglia and matrix metalloproteinases involvement in neuroinflflammation and gliomas[J]. Clin Dev Immunol, 2013, 2013: 914104. DOI: 10.1155/2013/914104.
|
[2] |
Sato H, Takino T. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion[J]. Cancer Sci, 2010, 101(4): 843-847. DOI: 10.1111/j.1349-7006.2010.01498.x.
|
[3] |
Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma[J]. Cell, 2013, 155(2): 462-477. DOI: 10.1016/j.cell.2013.09.034.
|
[4] |
Lu X, Duan L, Xie H, et al. Evaluation of MMP-9 and MMP-2 and their suppressor TIMP-1 and TIMP-2 in adenocarcinoma of esophagogastric junction[J]. Onco Targets Ther, 2016, 9: 4343-4349. DOI: 10.2147/OTT.S99580.
|
[5] |
Schröder R, Feisel KD, Ernestus RI. Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas[J]. J Neurooncol, 2002, 56(2): 127-132. DOI: 10.1023/a:1014527929948.
|
[6] |
Mullerat J, Deroide F, Winslet MC, et al. Proliferation and p53 expression in anal cancer precursor lesions[J]. Anticancer Res, 2003, 23(3C): 2995-2999.
|
[7] |
Liu M, Lawson G, Delos M, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations[J]. Head Neck, 2003, 25(4): 280-288. DOI: 10.1002/hed.10218.
|
[8] |
Arshad H, Ahmad Z, Hasan SH. Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival[J]. Asian Pac J Cancer Prev, 2010, 11(6): 1637-1640.
|
[9] |
魏方, 强铭, 吴陈新, 等. VEGF、Ki-67在人脑胶质瘤中的表达及恶性程度相关性分析[J]. 中国临床实用医学, 2016, 7(2): 56-58. DOI: 10.3760/cma.j.issn.1673-8799.2016.02.016.
|
[10] |
Bartussek C, Naumann U, Weller M. Accumulation of mutant p53 (V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status[J]. Exp Cell Res, 1999, 253(2): 432-439. DOI: 10.1006/excr.1999.4654.
|
[11] |
Romano FJ, Guadagno E, Solari D, et al. ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: a clinicopathologic study[J]. J Cell Biochem, 2018, 119(6): 4867-4877. DOI: 10.1002/jcb.26699.
|
[12] |
Jiang XJ, Lin J, Cai QH, et al. CDH17 alters MMP-2 expression via canonical NF-κB signalling in human gastric cancer[J]. Gene, 2019, 682: 92-100. DOI: 10.1016/j.gene.2018.05.042.
|
[13] |
Xu J, E C, Yao Y, et al. Matrix metalloproteinase expression and molecular interaction network analysis in gastric cancer[J]. Oncol Lett, 2016, 12(4): 2403-2408. DOI: 10.3892/ol.2016.5013.
|
[14] |
Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression[J]. FASEB J, 2002, 16(6): 555-564. DOI: 10.1096/fj.01-0790com.
|
[15] |
Pei J, Park IH, Ryu HH, et al. Sublethal dose of irradiation enhances invasion of malignant glioma cells through p53-MMP2 pathway in U87MG mouse brain tumor model[J]. Radiat Oncol, 2015, 10: 164. DOI: 10.1186/s13014-015-0475-8.
|
[16] |
Yi GZ, Feng WY, Zhou Q, et al. The impact of MMP-2 and its specific inhibitor TIMP-2 expression on the WHO grade and prognosis of gliomas in Chinese population: a meta-analysis[J]. Mol Neurobiol, 2017, 54(1) :22-30. DOI: 10.1007/s12035-015-9539-x.
|
[17] |
Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation[J]. J Biol Chem, 2001, 276(10): 7549-7558. DOI: 10.1074/jbc.M010242200.
|
[18] |
Yi X, Guo J, Guo J, et al. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion[J]. Sci Rep, 2017, 7(1): 3568. DOI: 10.1038/s41598-017-03362-z.
|
[19] |
Pietruszewska W, Bojanowska-Poźniak K, Kobos J. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study[J]. Otolaryngol Pol, 2016, 70(3): 32-43. DOI: 10.5604/00306657.1202546.
|
[20] |
Wang Z, Wang B, Shi Y, et al. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2[J]. Oncogene, 2015, 34(11): 1407-1419. DOI: 10.1038/onc.2014.75.
|
[21] |
Valacca C, Tassone E, Mignatti P. TIMP-2 interaction with MT1-MMP activates the AKT pathway and protects tumor cells from apoptosis[J]. PLoS One, 2015, 10(9): e0136797. DOI: 10.1371/journal.pone.0136797.
|